Pfizer-BioNTech vaccine found effective against mutations in early studies
The first results of tests on new UK and SA variants are encouraging, with more studies in the offing
08 January 2021 - 13:40
New York — Pfizer and BioNTech’s Covid-19 vaccine appears to work against a key mutation in the highly transmissible new variants of the coronavirus discovered in Britain and SA, according to a laboratory study conducted by the US drugmaker.
The study by Pfizer and scientists from the University of Texas Medical Branch, which has not yet been peer-reviewed, indicated the vaccine is effective in neutralising virus with the N501Y mutation of the spike protein...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.